Investment Criteria 

While the merits of each investment will vary, we evaluate your venture according to the following criteria:
  • Must be referred by our professional network or syndication network.
  • Must show 12 months trailing revenue (exclusive of grants) that reflects growth on a month to month basis and ARR should be at least 90%.
  • FDA clearances must be achieved prior to deal investment.
  • IP is a benefit and all patents must be owned by the company to which the potential investment is being made. Acquisition of patents and licenses should indicate the terms of the acquisition and must be exclusive rights.
  • If no I.P. exists, the company should have "First Mover" status.
  • “Innovation” must have some proof of scalability and sustainability.
  • Strength of management team and advisors a must, particularly the CEO, supported by the MHS leadership assessment tool.
  • Exit projections must provide clarity of exit options (Strategic/PE/Family Offices) and valuations projections.
  • A cash flow forecast with a projection of being cash flow + within 18 months of investment. This is indicative of the more mature businesses in which we aspire to invest in on the development curve. 
  • Target Addressable Market size of $500M (TAM).
  • Return On Investment target range of 3x - 5x in 3 - 4 years. (Note: Average Angel Deal ROI is 2.6X in 3.5 Years).
  • Terms must include a redemption clause. SAFE notes will not be considered.
  • Majority shareholder rights to be secured either via a Board Membership, Observer role or right to access communication/pertinent board reports for TAF assignees to track performance.
  • Fund Lifetime is expected to be 7 Years. (2 -3 years to fully absorb deal flow and allowing 4 -5 years for ROI).
  • Geographic Focus – Southeast and Midwest United States.
  • A clear and meaningful point of difference should exist vs. competition.
Industry Sectors
  • Disruptive technology or SAS to replace outdated, inefficient business processes.
  • Fintech
  • EdTech
  • TeleHealth
  • Medical devices with appropriate clearances for go-to-market are acceptable
  • Pharma products will not be considered.